Clinical evidence indicates that cigarette smoking negatively impacts the incidence and severity of fatty liver disease, fibrosis progression, hepatocellular carcinoma development, and the outcomes of patients with advanced liver disease. The underlying mechanisms are complex and involve different pathophysiological pathways including oxidative stress and oncogenic signals. To coincide with World No Tobacco Day, 31 May, this EASL Studio discusses some of the pathophysiological mechanisms that drive the progression of liver disease and cancer risk in those who smoke. Faculty Prof. William Alazawi (Moderator)Prof. Debbie Shawcross (Moderator)Prof. Ramon Bataller (Faculty)Prof. Vanessa Stadlbauer-Köllner (Faculty)All EASL Studio Podcasts are available on EASL Campus.